Medisse BV, a leading innovator and developer of synthetic resorbable
soft tissue implants, today announced the successful treatment of the
first patient in a clinical trial for its first innovation, FlexiSurge® Adhesion
Barrier, which is designed to reduce adhesions formed after open
colorectal surgery procedures. The study, currently underway in the
Netherlands, marks a significant milestone in the development of the
Company's first product to revolutionize patient care.
The study, being conducted in three hospitals in the Netherlands, will
investigate the safety of FlexiSurge, and its ability to reduce
formation of adhesions after open colorectal surgery. Adhesions are
formed on average in 70-90% of open abdominal surgical procedures. These
adhesions can have severe clinical consequences like small bowel
obstructon - with a high mortality rate-, secondary infertility in
female, complications in re-operations and chronic abdominal pain.
FlexiSurge has the potential to make an enormous impact on colorectal
procedures and has been estimated as a $2-3B market WW.
"We are happy to have successfully treated the first patient in the
FlexiSurge study," said Prof Dr. ND Bouvy of the Academic Medical
Center, Maastricht, in The Netherlands. "We look forward to diminish the
problem of adhesion formation in the future by this promising
"The treatment of this first patient is a major milestone for our
company and will be our first class 3 product in humans," said Tjeerd
Homsma, Chief Executive Officer of Medisse. "Our FlexiSurge product has
the potential to revolutionize anti-adhesion treatment in abdominal
surgeries and address a huge cost to society for treatment of the
clinical consequences, >3B$ annually in the US alone. We are privileged
to work with such a renowned group of doctors who recognize the need for
this product on a daily basis."
Medisse BV is a leading innovator and developer of synthetic resorbable
soft tissue implants. The Company's first product, FlexiSurge Adhesion
Barrier, is currently tested in a clinical study to obtain the clinical
data needed for CE marking early in 2015. Medisse is also developing
anti-adhesive technologies for use on other implantable medical devices
like eg. hernia meshes. Medisse products are currently indicated for
investigational use only and have not yet been approved for medical use
in any market.
[ Back To NFVZone's Homepage ]